Changes in Hong Kong stocks | Genting Xinyao (01952) rose more than 3%, and Le Ruibo® was approved by the FDA and is expected to submit a BLA in Greater China in the first half of next year

The Zhitong Finance App learned that Genting Xinyao (01952) rose more than 3%. As of press release, it had risen 3.46% to HK$48.44, with a turnover of HK$131 million.

^{According to news, according to Genting Xinyao's WeChat account, on December 17, the company announced that the US Food and Drug Administration (FDA) has approved a biological product license application (BLA) for LIB Therapeutics' cardiovascular disease product LEROCHOLTM (generic name: lerodalcibep-liga) injection to reduce adult hypercholesterolemia (including heterozygous familial hypercholesterolemia) on the basis of diet control and exercise (} hEFH)) The patient's low density lipoprotein cholesterol (LDL-C) level. ^{In December 2025, Genting Xinyao and Hisense Biotech signed a licensing agreement and obtained an exclusive license to carry out subsequent clinical development, registration and commercialization of Lerodalcibep® (Lerodalcibep) in Greater China.}

Lorebot® is a third-generation PCSK9 inhibitor that combines a novel small molecule protein to help patients achieve and maintain their LDL-C control goals over the long term. ^{As the first PCSK9 inhibitor fusion protein, Leribot® has low immunogenicity and excellent safety.} Leroy Por ^® has been developed to be closer to patients' needs and more convenient. It can be self-administered by patients, injected once a month, and has a long period of room temperature stability (up to 3 months), which allows patients to choose when and where to use the medication, and can be easily stored or carried when traveling at home. ^{The above characteristics make Loribo® a unique alternative to approved PCSK9 inhibitors.}